MicroGravity: Just Another Research Environment is an event to help the Life Science sector and explore the value and opportunity from conducting research in Microgravity. This unique research environment holds significant potential but is not well understood by the Life Sciences sector.
This event aims to provide clarity, advice and ‘myth-busting’ insights that explain the benefits of Microgravity and encourage participants to co-create ideas and approaches for conducting research in this domain.
As interest in Microgravity-enabled research accelerates, this event will bridge the current academic, commercial, and regulatory gaps between the space and life science sectors.
This event will:
- Demystify microgravity research through expert insights and myth-busting sessions, highlighting the scientific benefits of this unique environment.
- Enable co-creation, giving participants the opportunity to develop concepts and approaches for conducting research in microgravity.
- Map the UK innovation landscape, identifying organisations and activities already engaged in microgravity Life Science research.
- Promote future Space/Life Science sector collaboration for Microgravity Life Sciences, fostering synergies across industry and academia.
- Showcase the roles of UK Space Clusters and Health Innovation Networks in supporting microgravity enabled Life Science innovation.
Why Attend?
You can help shape the emerging Microgravity Life Science economy as Europe moves toward sovereign access to this environment through new launchers, free-flyers, and bio-research platforms.
Who Should Attend?
We welcome organisations from across the UK, particularly from the South-East, East of England, Wales, and the North-West. Attendees will include innovators and leaders from academia, biotech, pharma, and the wider Life Science community.
We also welcome companies with strong Microgravity potential including:
- Immunology & Immuno-Oncology: Autoimmunity, cell-based therapies, immune-circuit stress testing
- Geroscience & Immune Ageing: Ageing biology, neurodegeneration, resilience biomarkers, cardiomyocyte studies
- Advanced Modalities & Bioprocessing: Biologics, gene and cell therapy, crystallisation, VLP/AAV quality attributes, in-space biomanufacturing
- Organoids & Organ-on-Chip: BBB, gut, kidney, and brain models—towards tissue engineering, bioprinting, and regenerative medicine